HMGB1 as biomarker and drug target

详细信息    查看全文

• 作者：Emilie Venereau^a ; ^b ; Federica De Leo^c ; Rosanna Mezzapelle^a ; Giorgia Careccia^a ; ^d ; Giovanna Musco^c ; Marco E. Bianchi^a ; ^e ; ^{bianchi.marco@hsr.it" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Sepsis ; Autoimmunity ; Cancer ; Trauma ; Inflammation ; Redox
• 刊名：Pharmacological Research
• 出版年：2016
• 出版时间：September 2016
• 年：2016
• 卷：111
• 期：Complete
• 页码：534-544
• 全文大小：2216 K

文摘

High Mobility Group Box 1 protein was discovered as a nuclear protein, but it has a “second life” outside the cell where it acts as a damage-associated molecular pattern. HMGB1 is passively released or actively secreted in a number of diseases, including trauma, chronic inflammatory disorders, autoimmune diseases and cancer. Extracellular HMGB1 triggers and sustains the inflammatory response by inducing cytokine release and by recruiting leucocytes. These characteristics make extracellular HMGB1 a key molecular target in multiple diseases. A number of strategies have been used to prevent HMGB1 release or to inhibit its activities. Current pharmacological strategies include antibodies, peptides, decoy receptors and small molecules. Noteworthy, salicylic acid, a metabolite of aspirin, has been recently found to inhibit HMGB1. HMGB1 undergoes extensive post-translational modifications, in particular acetylation and oxidation, which modulate its functions. Notably, high levels of serum HMGB1, in particular of the hyper-acetylated and disulfide isoforms, are sensitive disease biomarkers and are associated with different disease stages. In the future, the development of isoform-specific HMGB1 inhibitors may potentiate and fine-tune the pharmacological control of inflammation. We review here the current therapeutic strategies targeting HMGB1, in particular the emerging and relatively unexplored small molecules-based approach.